Daniel O’Day

Chairman and Chief Executive Officer, Gilead Sciences, Inc.

Daniel O’Day joined Gilead Sciences in March 2019 as Chairman of the Board of Directors and Chief Executive Officer.

Prior to Gilead, Daniel served as the Chief Executive Officer of Roche Pharmaceuticals. His career at Roche spanned more than three decades, during which he held a number of executive positions in the company’s pharmaceutical and diagnostics divisions in North America, Europe and Asia. He served as a member of Roche’s Corporate Executive Committee, as well as on a number of public and private boards, including Genentech, Flatiron Health and Foundation Medicine.

Daniel O’Day holds a bachelor’s degree in biology from Georgetown University and an MBA from Columbia University in New York. He currently serves on the board of directors for the Pharmaceutical Research and Manufacturers of America organization and Galapagos NV.

Andrew Dickinson

Chief Financial Officer

Andrew Dickinson serves as Gilead’s Chief Financial Officer, responsible for the oversight of the company’s global finance, corporate development, information technology, operations and strategy organizations.

Andy joined Gilead in 2016 and prior to his current role served as head of the company’s corporate development and strategy group. In that role, Andy drove all of Gilead’s licensing, partnership and acquisition transactions and guided investments into new areas. Prior to his tenure at Gilead, Andy was the global Co-Head of Healthcare Investment Banking at Lazard. Earlier in his career, he served as General Counsel and Vice President of Corporate Development at Myogen, Inc., which was acquired by Gilead in 2006.

Andy received his bachelor’s degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and his law degree from Loyola University of Chicago.

He sits on the board of the Fosun Pharma and Kite joint venture in China, which was established in 2017.

William A. Lee, PhD

Executive Vice President, Research

William Lee is the Executive Vice President of Research at Gilead, overseeing the company’s innovative research and preclinical programs across all therapeutic areas. Since joining Gilead in 1991, he has been responsible for the expansion of the company’s research programs, leading efforts to advance multiple products from early-stage research into clinical development. His contributions to the discovery of internal drug candidates and evaluation of external compounds have allowed Gilead to bring important new medicines to patients.

Prior to joining Gilead, Bill held positions at Syntex Corp. and California Biotechnology, Inc.

Bill received his bachelor’s degree in chemistry from the University of Massachusetts and his PhD in chemistry from the University of California, San Diego. He did postdoctoral work at the Ecole Polytechnique-Federale de Lausanne and the University of California, Santa Barbara.

Johanna Mercier

Chief Commercial Officer

Johanna Mercier serves as Gilead’s Chief Commercial Officer, with responsibility for the global commercialization of all the company’s medicines throughout the product lifecycle. Under her leadership, Gilead works to ensure that patients around the world have access to the company’s transformational medicines.

Johanna joined Gilead in 2019 after 25 years at Bristol-Myers Squibb, where she served in a number of executive leadership positions, gaining broad experience across geographies and in all aspects of the commercial business. In her time there, she successfully evolved the culture and drove strong commercial execution with double-digit growth and multiple launches that changed the standard of care in melanoma and renal cancers.

Johanna holds a bachelor’s degree in biology from the University of Montreal and an MBA from Concordia University.

She is a member of the board of the University of Southern California’s Leonard D. Schaeffer Center for Health Policy and Economics